Abstracts tagged "hyperuricemia"

Abstract Number: 0278 • ACR Convergence 2024
Efficacy and Safety of Genakumab versus Compound Betamethasone in Gout: The GUARD-1 Study
Yu Xue¹, Tianshu Chu², Jiankang Hu³, Wei Gou⁴, Ning Zhang⁵, Juan Li⁶, Jing Yu⁷, Songping Li⁸, Songbin Li⁹, Long Qian¹⁰, Xinwang Duan¹¹, Lihua Duan¹² and Hejian Zou¹, ¹Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China (People's Republic), ²Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, Zhengzhou, China (People's Republic), ³Department of Rheumatology, Pingxiang People's Hospital, Pingxiang, China, Pingxiang, China (People's Republic), ⁴Department of Rheumatology, Hebei Petro China Central Hospital, Langfang, China, Langfang, China (People's Republic), ⁵Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shenyang, China (People's Republic), ⁶Department of Rheumatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China, Haikou, China (People's Republic), ⁷Department of Rheumatology, The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), ⁸Department of Rheumatology, The First Affiliated Hospital of Ganna Medical University, Ganzhou, China, Ganzhou, China (People's Republic), ⁹Department of Rheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), ¹⁰Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), ¹¹Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, Nanchang, China (People's Republic), ¹²Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)
Background/Purpose: The GUARD (Genakumab in high Uric Acid-induced Arthritis/goutfor Resolution and Delay study) program was designed to investigate the efficacy and safety of Genakumab, a…
Abstract Number: 1085 • ACR Convergence 2024
Pharmacokinetics and Pharmacodynamics of Tigulixostat in Participants with Mild, Moderate, and Severe Renal Impairment
Ashish Kumar¹, Ali Hariri¹, Yunjung Lee² and Minhyung Lee², ¹LG Chem Life Sciences USA, Boston, MA, ²LG Chem, Seoul, Republic of Korea
Background/Purpose: Tigulixostat is a potent and highly selective non-purine based xanthine oxidase inhibitor (XOi) being investigated for the management of hyperuricemia in patients with gout.…
Abstract Number: 1094 • ACR Convergence 2024
Longitudinal Analysis of Serum Urate in Prediabetic Phase
Javier Marrugo¹, Leah Santacroce¹, Misti Paudel², Sho Fukui³, Sara Tedeschi¹ and Daniel Solomon⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Brigham and Women's Hospital, Newton, MA
Background/Purpose: More than 460 million people worldwide are currently living with prediabetes, a condition that not only predisposes individuals to diabetes (DM) but also to…
Abstract Number: 1095 • ACR Convergence 2024
The Incidence of Gout Among Individuals with Hyperuricemia over Time – an Insight from a Nationwide Cohort Study
Shay Brikman¹, Amir Bieber², Liel Serfaty, MA³, Ran Abuhasira, MD, PhD⁴, Nadav Rappoport⁵ and Naomi Schlesinger⁶, ¹Emek Medical Center, Afula, Israel, ²Emek Medical Center, Clalit Health Services, Raanana, Israel, ³Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel, ⁴Clinical Research Center, Soroka University Medical Center, Be'er Sheva, Israel, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁶University of Utah, Salt Lake City, UT
Background/Purpose: Hyperuricemia is considered the most important risk factor for developing Gout, the most common adult inflammatory arthritis. Hyperuricemia is defined by a serum urate…
Abstract Number: 1096 • ACR Convergence 2024
Exploring Multi Factorial Model for the Prediction of Gout in Patients with Hyperuricemia
Shay Brikman¹, Liel Serfaty, MA², Ran Abuhasira, MD, PhD³, Naomi Schlesinger⁴, Nadav Rappoport⁵ and Amir Bieber⁶, ¹Emek Medical Center, Afula, Israel, ²Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel, ³Clinical Research Center, Soroka University Medical Center, Be'er Sheva, Israel, ⁴University of Utah, Salt Lake City, UT, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁶Emek Medical Center, Clalit Health Services, Raanana, Israel
Background/Purpose: Hyperuricemia (HU) is considered the most important factor preceding Gout. Yet, only a portion of hyperuricemic people develop Gout. Using a machine learning modeling…
Abstract Number: 1097 • ACR Convergence 2024
CERT Score as a Potential Tool to Predict Cardiovascular Risk in Gout and Hyperuricemia
Blanka Stiburkova¹, Aleš Kvasnička², Barbora Pisklakova², Jakub Rozhon², Karel Pavelka³ and David Friedecky², ¹Institute of Rheumatology, Prague, Czech Republic and Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague, Czech Republic, ²Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Czech Republic, ³Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Asymptomatic hyperuricemia and gout are two clinical conditions associated with a high risk of cardiovascular events and mortality. Recent data suggest that the number…
Abstract Number: 1098 • ACR Convergence 2024
Prognostic Value of Hyperuricemia in Developing Cardiovascular Events in Patients with Chronic Inflammatory Arthritis: A 10-Year Prospective Study
Antonio Avilés¹, Zulema Plaza², Fernando Sánchez-Alonso³, Santos Castañeda⁴, Benjamin fernandez-Gutierrez⁵, César Díaz⁶, Pilar Font⁷, Olga Martinez⁸, Emilio Giner⁹, José Miguel Senabre¹⁰, Amalia Rueda¹¹, Ana Perez¹², Gines Sanchez¹³, Carlos Gonzalez¹⁴, Javier García¹⁵, Javier Llorca¹⁶, Miguel Angel Gonzalez-Gay¹⁷ and Mariano Andres¹⁸, and CARMA project, reserch group., ¹Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain, ²Fundacion Española de Reumatología, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, ⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁸Hospital Universitario de Salamanca, Zamora, Spain, ⁹Hospital Royo Villanova, Teruel, Spain, ¹⁰Hospital Marina Baixa Alicante, Alicante, Spain, ¹¹Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, ¹²Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, ¹³Hospital General de Albacete, Albacete, Spain, ¹⁴Hospital Universitario Lucus Augusti; Biodiscovery HULA-USC Group, Instituto de Investigación Sanitaria de Santiago de Compostela IDIS., Lugo, Spain, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, ¹⁷University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ¹⁸Hospital General Universitario de Alicante, Alicante, Spain
Background/Purpose: The role of concurrent hyperuricemia as a cardiovascular risk factor in patients with chronic inflammatory arthritis (CIA) has yet to be studied. We aim…
Abstract Number: 1100 • ACR Convergence 2024
Coronary Dual-Energy Computed Tomography for the Detection of Monosodium Urate Crystal Deposition in the Arteries of Individuals with and Without Gout (CORODECT): A Multi-Center Prospective Imaging Study
Chio Yokose¹, Tristan Pascart², Mangun Randhawa³, Padraic Kennedy⁴, Christoph Schwabl⁵, saiajay chigurupati³, Bohang Jiang³, Leo Lu⁶, Julia Held⁵, Gerlig Widmann⁵, F. Joseph Simeone³, Brian Ghoshhajra³, Adnan Sheikh⁴, Kamran Shojania⁴, Gudrun Feuchtner⁵, Andrea Klauser⁵, Savvas Nicolaou⁴, Jean-François Budzik², Fabio Becce⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Waltham, MA, ²Lille Catholic University, Lille, France, ³Massachusetts General Hospital, Boston, MA, ⁴Vancouver General Hospital, Vancouver, Canada, ⁵Medical University Innsbruck, Innsbruck, Austria, ⁶Arthritis Research Canada, Vancouver, BC, Canada, ⁷Lausanne University Hospital (CHUV), Lausanne, Switzerland, ⁸Massachusetts General Hospital, Lexington, MA
Background/Purpose: Prior dual-energy CT (DECT) studies have suggested that monosodium urate (MSU) crystals may be present in the coronary arteries of patients with gout. However,…
Abstract Number: 1898 • ACR Convergence 2024
Hyperuricemia Is Associated with Higher Levels of Fasting Plasma Glucose and Insulin Resistance in Non-diabetic Subjects
Janis Timsans¹, Jenni Kauppi¹, Anne Kerola², Vappu Rantalaiho³, Hannu Kautiainen⁴ and Markku Kauppi², ¹Päijät-Häme Central Hospital, Lahti, Finland, ²Päijät-Häme Central Hospital, University of Helsinki, Lahti, Finland, ³Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ⁴Folkhälsan Research Center, Helsinki, Finland
Background/Purpose: Disorders of glucose metabolism are well-known major contributors to morbidity and mortality. Elevated serum uric acid (SUA), a key precursor of gout attacks, is…
Abstract Number: 2013 • ACR Convergence 2024
Elevated Serum Allantoin and Allantoin/uric Acid Ratio as Indicators of Oxidative Stress in Severe Gout and Cardiovascular Comorbidities
Lenka Hasikova¹, Petr Kozlik², Kveta Kalikova³, Petr Dusek⁴, Marketa Pavlikova¹, Blanka Stiburkova⁵ and Jakub Závada⁶, ¹Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Department of Neurology and Centre of Clinical Neuroscience and Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic, Prague, Czech Republic, ⁵Institute of Rheumatology, Prague, Czech Republic and Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Uric acid (UA) can be non-enzymatically oxidized into allantoin and other products by reactive oxygen species under conditions of increased oxidative stress. Consequently, allantoin…
Abstract Number: 2020 • ACR Convergence 2024
Prediction of the Response of Patients with Chronic Uncontrolled Gout to Pegloticase
Peter Lipsky¹ and anthony yeo², ¹AMPEL BioSolutions, Charlottesville, VA, ²Independent consultant, Ann arbor, MI
Background/Purpose: Pegloticase is a pegylated recombinant uricase approved for treatment of chronic uncontrolled gout. Because of the development of anti-drug antibodies (ADA), persistent urate lowering…
Abstract Number: 2023 • ACR Convergence 2024
A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout
Frank Fan¹, Riyong Liu¹ and Yu Wang², ¹Chongqing PegBio Biopharm Co.,Ltd., Chongqing, China (People's Republic), ²Hangzhou Grand Biologic Pharmaceutical, Inc., Hangzhou, China (People's Republic)
Background/Purpose: For patients with refractory chronic gout, i.e., those who have frequent gout flares and/or persistent tophi despite treatment with the highest tolerable doses of…
Abstract Number: 2024 • ACR Convergence 2024
Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis
Chio Yokose¹, saiajay chigurupati², Bohang Jiang², Kiara Tan², Natalie McCormick² and Hyon K. Choi³, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Hypertension is the most common comorbidity among patients with gout, with a prevalence of nearly 75% among patients with gout. Losartan and calcium channel…
Abstract Number: 2127 • ACR Convergence 2024
Relationship Between Serum Uric Acid and Trabecular Bone Score (TBS) in Healthy Population
Isabella Silvestre Ignarro¹, Gabriela Tieme Ochikubo², Liliam Takayama³, Valeria de falco Caparbo², Camille Pinto Figueiredo², Marcos Rafael Nogueira Cavalcanti¹, Angelita Gomes De Souza¹, Isabela Judith Martins Bensenor¹, Ricardo Fuller¹ and Diogo Domiciano⁴, ¹Bone Metabolism Laboratory, Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ²Bone Metabolism Laboratory, Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, São Paulo, SP, Brazil, ³Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil
Background/Purpose: Serum uric acid (UA) has been postulated to play a role against bone loss due to antioxidant mechanisms. Some studies have shown association between…
Abstract Number: 1816 • ACR Convergence 2023
Hyperuricemia – Especially “Metabolic Hyperuricemia” – Is Independently Associated with Higher Risk of Fatty Liver
Janis Timsans¹, Jenni Kauppi¹, Hannu Kautiainen² and Markku Kauppi³, ¹Päijät-Häme Central Hospital, Lahti, Finland, ²University of Helsinki, Folkhälsan Research Center, Helsinki, Finland, ³University of Helsinki, Helsinki, Finland
Background/Purpose: Elevated serum uric acid (SUA) level is rather prevalent in the general population, and it is associated with numerous comorbidities and mortality. Etiology of…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].